Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Federal Regulations on Privacy and A.I.
Linda Moore, president and CEO of Technet, explains why the U.S. should be a leader in A.I., plus why deepfakes and misinformation could be a concern during the election season.
Load More